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The immunomodulatory characteristics of mesenchymal stromal cells (MSCs) may lead to multifaceted strate-
gies in rejection of organ transplantation. This study was designed to investigate, first, the effect of the donor-
type MSCs from Wistar rats on the immune system of immunocompetent Lewis rats and, second, the rejection 
responses in a renal transplantation model of Wistar to Lewis. In the first experimental model, MSCs from the 
bone marrow induced a systemic immune response in the immunocompetent Lewis rats, characterized by two 
different phases. In the initial phase (days 1–3 after MSCs infusion), the main findings were a decrease in the 
percentage of the main peripheral blood (PB) lymphocyte subpopulations [T cells, B cells, and natural killer 
(NK) cells], an increase in the FOXP3 MFI in Tregs, and an elevated concentration of circulating proinflam-
matory cytokines (IL-1b and TNF-a). In the late phase (days 4–6), the percentage of T cells, B cells, and NK 
cells returned to baseline levels; the concentration of circulating IL-1b and TNF-a decreased; and the level 
of anti-inflammatory cytokines (IL-10 and IL-4) increased with respect to the initial phase. In the allogeneic 
kidney transplantation model, rats were randomized into four groups: nontreated, cyclosporine oral adminis-
tration, and two groups of rats treated with two different schedules of MSC infusion: 4 days (MSCs-4) and 
7 days (MSCs-7) before kidney transplantation and in both a further infusion at the day of transplantation. 
Both MSC treatments decreased the percentage of T, B, and NK cells in PB. Creatinine levels, survival, and 
histological parameters were better in MSCs-7 than in MSCs-4. We can conclude that MSCs, by themselves, 
produce changes in the immune system; they do not need a pathological condition to produce immunomodula-
tory responses. In the renal allograft model, the optimal time schedule for MSC infusion before grafting was 
7 days to prevent acute rejection.
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INTRODUCTION
Mesenchymal stromal cells (MSCs) are found in a var-
iety of tissues, including bone marrow, skin, and adipose 
tissue1. They are of interest because of their potential 
therapeutic effects2 that are mediated by multiple mecha-
nisms such as immunomodulatory effects through the 
secretion of regulatory cytokines3, activation of regulatory 
immune cells4,5, and the capacity to increase tissue repair 
through the secretion of antiapoptotic6, antifibrotic7, and 
proangiogenic factors8. Extensive in vitro studies have 
demonstrated that MSCs are capable of suppressing T-cell 
proliferation, influencing dendritic cell maturation and 
function, suppressing B-cell proliferation and terminal 
differentiation, and modulating other immune cells such 
as natural killer (NK) cells and macrophages9,10. These 
complex characteristics indicate that MSCs have multiple 
therapeutic effects in various diseases and/or organs11,12.
Organ transplantation is the only definite treatment 
for many critical diseases of the liver, kidney, heart, and 
other organs. Although it is the primary therapeutic option 
at present, organ transplantation is still burdened by the 
need for lifelong immunosuppression to prevent graft 
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rejection. Drugs currently in use for immunosuppression 
induction and maintenance include a variety of immuno-
suppressants that frequently cause severe side effects. 
Recently, in vitro expanded MSCs have been applied in 
preclinical and clinical studies in the treatment of graft-
versus-host disease (GVHD)13, multiple sclerosis14, sys-
temic lupus erythematosus15, and renal transplant16,17, 
with varying levels of success.
The in vivo immunomodulatory properties of MSCs 
have been inferred mainly from the in vitro studies. 
However, in vivo models or even clinical trials may fall 
far from in vitro observations18. In this regard, several 
issues should be examined in the search for MSC-based 
optimal effective regimens.
The present study was designed to (1) analyze the 
peripheral immunomodulatory response induced upon 
intravenous (IV) infusion of MSCs in immunocompetent 
rats, (2) investigate the peripheral immune response and 
the MSC-mediated modulation of acute rejection in a rat 
model of allogeneic kidney transplantation, and (3) find 
the optimal timing for infusion of MSCs in this setting.
MATERIALS AND METHODS
Isolation and Culture of Bone Marrow Rat MSCs
All procedures and animal housing conditions were in 
accordance with the Guidelines of the Committee on the 
Care and Use of Laboratory Animals and Good Laboratory 
Practices at the University of Barcelona. Bone marrow 
cells were extracted from Wistar rats (250 g; Charles 
River Laboratories, Barcelona, Spain) and were flushed 
out of the tibias and femurs with  phosphate- buffered 
saline (PBS; BD Biosciences, Madrid, Spain) and passed 
through a 70-µm mesh. After washing, cells were trans-
ferred to T-75 flasks at a density of 9 ́  105 cells/cm2 and 
maintained in modified Eagle’s medium-a (MEM-a) 
supplemented with 2 mM L-glutamine, 1% penicillin 
and streptomycin, and 15% fetal bovine serum (FBS) 
(all from Lonza, Madrid, Spain). After 24 h, medium 
and nonadherent cells were removed, and fresh medium 
was added.
Characterization of MSCs
For immunophenotyping, MSCs were harvested and 
stained with CD90-allophycocyanin (APC) (Miltenyi 
Biotec, Madrid, Spain), CD73-phycoerythrin (PE) (Abd 
Serotec, Raleigh, NC, USA), CD45-fluorescein isothio-
cyanate (FITC), CD34-PERCP (BD Biosciences), major 
histocompatibility com plex I (MHC-I)-FITC (BD Bio-
sciences), and MHC-II-FITC (BD Biosciences). Samples 
were analyzed on a fluorescence-activated cell sorting 
(FACS) Canto II flow cytometer (BD Biosciences, San 
Jose, CA, USA) using the FACSDiva software.
MSCs were proven to be multipotent with a rat 
mes enchymal stem cell functional identification kit, 
following the manufacturer’s instructions (R&D Systems, 
Madrid, Spain).
Infusion of MSCs in Immunocompetent Rats
One million MSCs (passages 3–5) from Wistar rats 
in 300 µl of PBS were infused intravenously through the 
dorsal penis vein of inbred Lewis rats. Every 24 h for 
6 days, blood was collected in heparin lithium tubes. The 
main subpopulations of peripheral blood (PB) cells were 
analyzed with flow cytometry. Two experiments were 
carried out, totaling three animals per experiment.
Quantification of Circulating Donor-Specific Antibodies 
in Immunocompetent Rats
The presence of circulating class I and class II donor-
specific antibodies (DSAs) was quantified in immuno-
competent rat serum samples that were incubated with 
donor spleen cells and measured with flow cytometry. 
After MSC infusion, serum samples were collected every 
24 h for 6 days. Donor splenocytes were isolated from 
Wistar rat spleens by Ficoll® (GE Healthcare, Madrid, 
Spain) density gradient and were freshly used. Different 
controls were added: serum from nontransplanted Lewis 
rat as naive and serum from a transplanted Lewis rat with 
high anti-MHC antibody titer as a positive control.
Briefly, 5 ́  105 splenocytes were incubated with 25 µl 
of serum from Lewis rats treated with MSCs for 30 min at 
room temperature, washed in PBS, incubated in the dark 
(30 min, 4°C) with a 1:25 mixture of anti-CD3 (eBiosci-
ence, Madrid, Spain) and anti-immunoglobulin G (IgG) 
Fc specific (Jackson ImmunoResearch, West Grove, PA, 
USA), and analyzed with flow cytometry. A fluorescence 
increase of 15% with regard to the negative control was 
considered positive.
Measurement of Soluble Cytokines  
in Immunocompetent Rats
Cytokines from the plasma were analyzed with cytom-
etric bead array immunoassay. The technique was based 
on the binding of particles that were labeled with differ-
ent fluorescence intensities to antibodies. The particles 
were bound by a covalent bond to an antibody against 
one of the cytokines: interferon-g (IFN-g), tumor necrosis 
factor-a (TNF-a), interleukin-2 (IL-2), IL-4, IL-1B, and 
IL-10 (BD Biosciences). This method allowed simulta-
neous determination of different cytokines in the same 
sample. Standard curves (0 to 5,000 pg/ml) were derived 
from a set of calibrators, and the same set was used for 
all assays. Then 50 µl of the sample or cytokine standard 
was added to the mixture of 50 µl of each of antibody-PE 
detector and antibody-bead reagent. The mixture (150 µl) 
was incubated for 160 min in the dark at room tempera-
ture and washed, and the test samples were acquired using 
the flow cytometer.
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Surgical Transplantation Technique and MSC Infusion
Inbred male Lewis rats (250 g) received an allogeneic 
kidney from Wistar rats (250 g). This strain combination 
was described by Azuma et al.19 as an acute allograft rejec-
tion model. The surgical technique has been described 
previously20. Briefly, kidneys were preserved for 40 min 
in Euro-Collins solution (Fagron Iberica, Barcelona, 
Spain) at 4°C. Kidneys were heterotopically anasto mosed 
to the aorta artery and cava vein, respectively, and the 
ureter end to end. Recipient rats were binephrectomized 
at the moment of transplantation.
Treatments and Design of Transplantation Groups: 
Follow-Up
Rats were randomized into the four groups listed 
below and then followed for 21 days:
Nontreated: rats received infusion of PBS (1. n = 7).
CsA: rats received a single daily dose of 5 mg/kg 2. 
cyclosporine (Novartis) by oral gavage for 21 days 
(n = 7).
MSCs-4: rats received two infusions of MSCs (1 3. ´ 106 
cells), at day 4 before renal transplantation and at 1 h 
after surgery (n = 5).
MSCs-7: rats received two infusions of MSCs (1 4. ´ 106 
cells), at day 7 before renal transplantation and at 1 h 
after surgery (n = 5).
PB samples were collected from the tail vein before 
surgery, on day 7 posttransplant (post-tx), and on the day 
of sacrifice in order to study cell subpopulations. The ani-
mals were euthanized with isoflurane when they appeared 
to be clinically ill, suggestive of renal failure, or at day 
21 after surgery when the outcome was excellent. To 
monitor renal function, serum creatinine was determined 
with Jaffe reaction (Autoanalyzer; Olympus, Hamburg, 
Germany) at baseline and every 2 days, beginning the day 
before surgery. Upon sacrifice, grafted kidneys were pro-
cessed for histological studies.
Flow Cytometry
PB samples were incubated with an antibody cock-
tail to analyze lymphocyte subsets: mouse anti-rat CD3-
FITC, mouse anti-rat CD45ra-PE, and mouse anti-rat 
CD163-APC (BD Biosciences). Another sample was also 
incubated with a combination of PE-conjugated mouse 
anti-rat forkhead box P3 (FOXP3) antibody (eBiosci-
ence), CD3-PE-cyanine 7 (Cy7), CD4-FITC, and CD25-
Alexa fluor 488. The cells were then analyzed with flow 
cytometry. For FOXP3 staining, an intracellular staining 
buffer set (eBioscience) was used following the manufac-
turer’s instructions.
Histological Studies
Coronal 1- to 2-µm-thick slices of graft kidneys were 
fixed in buffered formalin (Sigma-Aldrich, Madrid, Spain), 
dehydrated, and embedded in paraffin. For light micros-
copy, 3- to 4-µm-thick tissue sections were stained with 
hematoxylin and eosin (H&E) and periodic acid–Schiff 
(PAS; Sigma-Aldrich). A blinded pathologist assessed all 
sections for tubulitis, interstitial infiltration, vasculitis, 
glomerulitis, tubular necrosis, glomerular necrosis, and 
interstitial fibrosis, following the Banff criteria for acute/
active lesion scoring21. A global SCORE was defined as a 
summary of individual Banff parameters.
Paraffin-embedded tissue sections were immuno-
peroxidase-stained complement component 4 C4d (1:30; 
Biomedica Gruppe, Vienna, Austria). Negative controls 
were carried out by immunostaining-matched serial sec-
tions without the primary antibodies. C4d assessed in 
peritubular capillaries and glomeruli was semiquanti-
tatively scored: 0 denoted negative staining; 1, positive 
staining in <25% of the sample; 2, positive staining in 
25%–50%; 3, positive staining in 50%–75%; and 4, posi-
tive staining in 75%–100%.
Statistical Analysis
All results were expressed as mean ± standard devia-
tion (SD). Differences between time points were evalu-
ated using the Student’s t-test, and values of p < 0.05 were 
considered to be statistically significant. Statistical dif-
ferences between treatment groups were evaluated using 
single-factor or two-factor, without replication, analysis 
of variance (ANOVA). Post hoc analysis was performed 
using the Tukey–Kramer method because group sizes 
varied between experimental groups. The software used 
was StatView (SAS, Cary, NC, USA).
RESULTS
Isolation, Characterization, and Labeling of MSCs
Adherent cells displayed typical MSC morphology, 
namely, a spindle shape or flat-polygonal appearance 
(Fig. 1A). Cells were used at passages 3–5. The multi-
potency of the expanded MSCs was assessed by differ-
entiating the cells into adipocytes (Fig. 1B), osteoblasts 
(Fig. 1C), and chondroblasts (Fig. 1D). Flow cytometry 
(Fig. 1E) analysis demonstrated positive staining for 
CD90 (93.2 ± 5.1%) and CD73 (89.6 ± 10.1%), and low 
expression of MHC-I (Fig. 1F) (92.5 ± 8.4%) but negative 
for CD34, CD45, and MHC-II, indicating a mesenchymal 
rather than hematopoietic origin.
MSCs Alter the Percentage of the Main Lymphocyte 
Subsets in PB
In Figure 2A, a representative study of the distribu-
tion of the major lymphocyte subpopulation in the PB of 
naive Lewis rats is depicted. Lymphocyte population was 
defined using a forward scatter-height (FSC-height)/side 
scatter-height (SSC-height) dot plot (G1). Subsequently, 
T cells, B cells, NK cells, and NK cells derived from 
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T cell (NKT) lymphocytes in the G1 population were 
assessed using a CD3-FITC/CD45ra-PE and CD3-FITC/
CD161-APC dot plot.
At 3 days after infusion, the percentages of T and 
B cells (CD3: 26.6 ± 4.7%; CD45ra: 16.9 ± 3.6%) were 
both significantly reduced compared to baseline (CD3: 
50 ± 2.5%, p < 0.05; CD45ra: 25.9 ± 0.8%, p < 0.05) (Fig. 2B 
and C). Rat NK cells were defined as CD3−CD161+, and 
NKTs as CD3+CD161+. Notably, NK cells showed an 
about fourfold drop at day 3 after infusion (CD161: 
1.3 ± 1.3%) with respect to baseline (5.9 ± 2.1%, p < 0.05) 
(Fig. 2D). In contrast, the percentage of NKTs increased 
at day 3 after infusion (7.6 ± 0.8%) with respect to base-
line (3.1 ± 0.4%, p < 0.05) (Fig. 2E).
MSCs Increase FOXP3 Expression in Regulatory T Cells
We next investigated whether MSCs might influence 
the regulatory T cells (Tregs) profile. To this end, the 
CD4+CD25+FOXP3+ lymphocyte subpopulation was ana-
lyzed with flow cytometry (Fig. 3A). The percentage 
of Tregs with respect to the total number of CD3+ cells 
remained stable after MSC infusion (range: 3.3%–3.7%) 
at all of the time points (Fig. 3B). Interestingly, in con-
trast to Treg frequencies, considerable differences in the 
mean fluorescence intensity (MFI) of FOXP3 in Tregs at 
different time points were observed (Fig. 3C). The MFI of 
FOXP3 in Tregs increased at day 1 (1,351.5 ± 60.5 MFI) 
compared with baseline (743.5 ± 100.7 MFI, p < 0.05) and 
peaked at day 4 (1,831 ± 124 MFI).
Circulating Donor-Specific Antibodies (DSAs)
Donor splenocytes obtained from spleens of naive 
Wistar rats were cultured with serum from MSC-treated 
immunocompetent Lewis rats. DSA assay was negative 
at all time points; the fluorescence increase was lower 
than 15% with regard to the negative control (data not 
shown).
Effects of IV Infusion of MSCs on the  
T Helper 1 (TH1)/TH2 Balance
To analyze whether the MSCs could modify the molec-
ular circulating environment in healthy animals, some 
TH1/TH2 cytokines were measured in serum at various 
time points. After administration of MSCs, we observed 
a dynamic response, with two distinct phases (Fig. 4). An 
initial phase, between day 1 and day 3 after MSC infu-
sion, was characterized by an increase in the TH1 cyto-
kines IL-1B (1.8-fold) and TNF-a (2-fold) with respect to 
the baseline. A later phase, between day 5 and day 6, saw 
the concentration of proinflammatory cytokines decrease 
significantly and return to baseline levels (Fig. 4A). In 
contrast, in this later phase, TH2 cytokine concentrations 
Figure 3. (A) Phenotypic analysis of regulatory T cells (Tregs) (CD3+CD4+CD25+FOXP3+) in PB by flow cytometry. (B) Kinetics of 
Treg percentage and (C) forkhead box P3 (FOXP3) expression by flow cytometry in Tregs. MFI, mean fluorescence intensity.
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started to increase at day 4 and picked up at day 6 (IL-10: 
1.25-fold; IL-4: 6-fold) with respect to the baseline 
(Fig. 4B). No significant changes in serum concentration 
of IFN-g or IL-2 were observed (data not shown).
Effects of MSC Administration on Lymphocyte Subsets 
in Renal Grafted Rats
No presurgical baseline levels of lymphocyte popu-
lations differed significantly between treatment groups. 
The analysis revealed that there were no statistical differ-
ences in the percentage of CD3+ cells between groups at 
day 7 post-tx and sacrifice point (Fig. 5A).
Post-tx levels of circulating CD45ra+ B cells were 
decreased in all groups at day 7 (CsA: 21.3 ± 1.5, p < 0.05; 
nontreated: 12.2 ± 4.2, p < 0.01; MSCs-4: 18.3 ± 4.8, p < 0.05; 
MSCs-7: 15.4 ± 2.9, p < 0.05) with respect to the baseline. 
At the point of sacrifice, CD45ra+ B cells in the CsA 
group (27.7 ± 3.5) returned to baseline levels, while in the 
other groups it continued to be clearly lower ( p < 0.05) 
(Fig. 5B).
The nontreated group showed an increase in the per-
centage of NK cells at day 7 post-tx (23.2 ± 6.6%) compared 
with the CsA (4.1 ± 1.3%, p < 0.01), MSCs-4 (12 ± 4.3%, 
p < 0.01), and MSCs-7 (9 ± 3.6%, p < 0.01) groups. At the 
time of sacrifice, the percentage of NK cells in each group 
was similar to the day 7 post-tx percentage (Fig. 5C).
At day 7 post-tx, the increase in NKTs varied between 
groups (CsA: 3.6 ± 0.9%; nontreated: 10.5 ± 0.6%, p < 0.01; 
MSCs-4: 9.2 ± 2.5%, p < 0.01; MSCs-7: 6.3 ± 1.5%, p <0.05) 
compared to baseline. It is important to note that the per-
centage of NKTs in the MSCs-7 group was clearly lower 
than that in the MSCs-4 ( p < 0.05). At sacrifice day, there 
Figure 4. Serum concentrations of cytokines after infusion of MSCs. Serum was collected at several time points after administration 
of MSCs. Concentrations of interleukin-1B (IL-1B), tumor necrosis factor-a (TNF-a), IL-10, and IL-4 were determined with cyto-
metric bead array immunoassay. (A, B) Measurements of six animals. Data represent the mean ±  standard deviation (SD). *p < 0.05. 
TH, T helper.
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were no differences between groups; all had returned to 
baseline values (Fig. 5D).
MSC Treatment Increased Tregs After Kidney 
Transplantation
The percentage of Tregs was increased at day 7 post-tx 
in both MSC groups (MSCs-4: 3.9 ± 0.7%; MSCs-7: 
3.8 ± 0.7%) and CsA (3.1 ± 0.3%) compared to the non-
treated group (2.2 ± 0.6, p < 0.05) group. At sacrifice, 
Tregs in MSCs-7 increased (5 ± 0.7%) with respect to day 
7 post-tx ( p < 0.05) and other groups (Fig. 6A). We ana-
lyzed FOXP3 expression in Tregs to assess its functional 
status22, and it was higher in both MSC groups (MSCs-4: 
2,308.8 ± 486.4 MFI; MSCs-7: 3,203.2 ± 810.4 MFI) with 
respect to the nontreated group (1,137.8 ± 267.9 MFI, 
p < 0.05) and CsA groups (1,569.4 ± 295.3 MFI, p < 0.05) 
at day 7 post-tx and with respect to baseline levels. At 
the time of sacrifice, the differences between groups were 
similar to that at day 7 post-tx (Fig. 6B).
Prolongation of Graft Survival and Protection  
of Graft Function With MSC Treatment
Survival mean of the nontreated group was 14.4 ± 
4.8 days (28.6% of survival). All the animals receiving a 
single daily dose of 5 mg/kg cyclosporine were alive at 
day 21 (100% of survival). The MSCs-4 showed a survival 
time of 17.6 ± 4.9 days (60% survival), and the MSCs-7 
group 20.2 ± 1.8 days (80% survival). The results clearly 
show that the infusion of MSCs significantly prolonged 
animal survival, and differences between the two MSC 
administrations were observed ( p < 0.05) (Fig. 7A).
Graft function was assessed serially by measuring 
the serum creatinine levels (Fig. 7B). In the nontreated 
rats, serum creatinine increased progressively from day 7 
and remained high throughout follow-up. In contrast, 
the CsA group maintained stable low serum creatinine 
levels throughout follow-up. MSC-infused rats showed 
different renal function profiles from the nontreated ani-
mals. MSCs-4 rats had increased serum creatinine earlier, 
Figure 5. Percentage of lymphocyte subsets in PB after renal transplantation. Graphic values (mean ± SD) represent circulating levels 
of each lymphocyte subset averaged for all transplant recipients within each respective treatment group at the indicated time points. 
(A) T cells (CD3+), (B) B cells (CD45ra+), (C) NK cells (CD3−CD161+), and (D) NKT (CD3+CD161+). Differences between time 
points were evaluated using the Student’s t-test, and values of p < 0.05 were considered to be statistically significant. MSCs, mesenchy-
mal stem cells; CsA, rats that received a single daily dose of 5 mg/kg cyclosporine by oral gavage for 21 days; post-tx, posttransplant; 
d, day.
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between day 3 and day 5, while the serum creatinine 
levels of MSCs-7 rats began increasing between day 5 and 
7 but with less severe kidney failure. Both MSC groups 
showed lower serum creatinine than the nontreated group 
(peak 5.8 ± 1.6 mg/dl); however, the MSCs-7 serum cre-
atinine (peak 2.4 ± 2.6 mg/dl) was significantly lower at 
all time points from day 3 than the MSCs-4 (peak 3.6 ± 
1.6 mg/dl, p < 0.05).
Graft Inflammatory Histopathological Status Depends 
on Timing of MSC Infusion
Nontreated rats showed severe inflammatory cell infil-
tration in all kidney compartments. This was accompanied 
by extensive glomerular necrosis associated with glo-
meruli infiltration and a considerable degree of second-
ary acute tubular necrosis. Cyclosporine administration 
clearly reduced the inflammation in all compartments, 
though a nonnegligible degree of tubulitis and intersti-
tial infiltration was seen. In accordance with the higher 
mortality and renal failure of MSCs-4, this group showed 
a higher global histological SCORE, even worse than 
nontreated animals (Fig. 8A). These differences were 
related in particular to a more severe degree of interstitial 
cell infiltration, but especially to a more severe vascu-
lar inflammation. This indicates an exacerbation of the 
graft inflammatory status. In contrast, when MSCs were 
infused 7 days before allotransplantation, a reduction in 
graft inflammation was observed, clearly better than both 
MSCs-4 and nontreated rats. Notably, this was accom-
panied by a lesser degree of secondary glomerular and 
tubular necrosis (Fig. 8B).
C4d deposition was completely absent in cyclosporine-
treated kidneys. In contrast, in nontreated kidneys, an 
intense deposition was seen in both glomeruli and inter-
tubular capillaries, completing the picture of humoral 
vascular rejection (Fig. 9A). In MSCs-7 kidneys, there 
was a clear reduction in C4d deposition, similar to that of 
cyclosporine kidneys. This was not the case with MSCs-4 
kidneys that showed the same C4d deposition as non-
treated kidneys (Fig. 9B).
Figure 6. Effects of MSCs on Tregs after kidney transplantation. (A) Percentage of Tregs (CD3+CD4+CD25+foxp3+) in rat PB and 
(B) mean fluorescence intensity (MFI) of FOXP3. Differences between time points were evaluated using the Student’s t-test, and values 
of p < 0.05 were considered to be statistically significant. CsA, rats that received a single daily dose of 5 mg/kg cyclosporine by oral 
gavage for 21 days; post-tx, posttransplant.
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DISCUSSION
In the present study, we investigated the effect of donor-
type MSCs in two different scenarios: the immune sys-
tem of immunocompetent rats and the rejection response 
modulation in a rat renal transplantation model. In the 
first experimental model, MSCs, after their IV adminis-
tration, elicited a systemic immune response in the immu-
nocompetent rats, characterized by two different phases. 
The initial phase, between day 1 and day 3 post-MSC 
infusions, was marked by a decrease in the percentage 
of T, B, and NK cells, an increase in the FOXP3 MFI in 
Tregs, and an elevated concentration of TH1 cytokines. 
Then there was a later phase, between day 5 and day 6, 
in which the percentage of the main PB cells returned 
to baseline percentages, the concentration of proinflam-
matory cytokines decreased, and, interestingly, the level 
of TH-2 cytokines increased with respect to the initial 
phase. The most interesting observation in our study is 
that MSCs do not need a pathological condition to pro-
duce immunomodulatory responses. They have, by them-
selves, the capacity to modulate the main cellular subsets 
of the immune system in the PB of healthy animals. 
These in vivo inherent characteristics of MSCs may offer 
beneficial effects in several disease models14,15, but how 
the immune-activating effects of MSC administration are 
produced remains unclear. Hoogduijn et al. reported that 
human MSCs induced an inflammatory response in mice 
2 h after their IV infusion23. Thus, it may be speculated 
that there is an immune response to foreign-like MSCs 
and/or to their unusual location, rather than an MSC-
specific response.
After the first part of our study, we investigated the 
effectiveness of the immunomodulatory response pro-
duced by MSCs in a rat model of allogeneic kidney trans-
plant. To this end, four groups of animals were studied: 
nontreated rats, rats receiving cyclosporine to prevent 
Figure 7. Effect of MSC infusion on animal survival and renal function in kidney transplant. (A) Animal survival was markedly pro-
longed when the animals were treated with CsA (rats that received a single daily dose of 5 mg/kg cyclosporine by oral gavage for 
21 days) or double infusion of MSCs at 7 days before the transplant and the same day of the transplant. (B) Graft function evaluated 
with serum creatinine (mg/dl). The level of serum creatinine was in line with survival results.
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acute rejection, and two groups receiving MSCs follow-
ing two different infusion schedules. In the first MSC 
administration group (MSCs-4), cells were infused at 
4 days pretransplantation (this time point was considered 
the early phase), and in the other group (MSCs-7), cells 
were infused 7 days pretransplantation (this time point 
was considered the later phase). Our results show that 
the percentages of the major lymphocyte subpopulations 
(T, B, and NK cells) after renal transplant, in the MSC 
groups, were closer to the CsA group than to the nontreated 
group. The lymphocyte subset most influenced by MSCs 
was NK cells. It has to be noted that the MSCs-7 group 
showed better results than the MSCs-4 group. NK cells are 
implicated in the early phase of innate immune responses, 
and consequently NK cell inhibition by MSCs could 
result in downregulation of the innate immune response 
potency, which could be beneficial for transplantation24,25.
Looking at the regulatory arm of the immune response, 
the percentage of Tregs in the MSCs-7 group was higher 
than in the MSCs-4. These results are in line with previous 
studies16,26 reporting that pretransplant infusion of MSCs 
induced tolerance, which was associated with Treg expan-
sion and impaired TH1 activity. In agreement with the 
phases of our study of immunocompetent rats, the timing 
Figure 8. MSC infusion transforms graft inflammatory histopathological status. (A) The global SCORE, which includes inflamma-
tory elemental lesions (tubulitis, glomerulitis, and vasculitis interstitial infiltrate) plus the subsequent tissue damage, shows the better 
histological picture in kidneys from the MSCs-7 group. (B) Representative microphotographs from each group: CsA (rats that received 
a single daily dose of 5 mg/kg cyclosporine by oral gavage for 21 days), little tubulitis and interstitial infiltrate; nontreated, severe 
exacerbation of inflammation in all renal compartments; MSCs-4, grade 3 vascular involvement and severe renal structural destruction 
with edema and inflammatory infiltration; MSCs-7, less severe vascular damage with well-preserved renal architecture. ATN, acute 
tubular necrosis.
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of MSC infusion clearly determines optimal clinical 
immunomodulation in the transplant model. Thus, results 
showed that MSCs-7 treatment absolutely improved 
the renal function and animal survival compared to the 
MSCs-4 group. The histology of the nontreated group 
rounded out a picture of humoral rejection with severe 
inflammation, increased glomerulitis and vascular cell 
infiltration, and prominent deposits of C4d in microves-
sels. The administration of MSCs 4 days before kidney 
grafting did not improve the histological signs of dam-
age compared to the nontreated animals. However, the 
infusion of MSCs 7 days before transplant improved the 
inflammatory graft status, with subsequently less acute 
tubular necrosis, glomerular necrosis, and C4d deposits.
Several authors have described different effects of 
MSCs in renal transplant. There are studies in which 
we find successful results27 or results that have failed28. 
When considering these studies, we observe that the 
dosage and timing of the MSC infusion are completely 
different. Koch et al.28 reported that in a model of acute 
kidney rejection, detrimental effects from MSC infu-
sion 4 days before the renal transplant were observed. In 
contrast, Perico et al. obtained better results when they 
infused the cells 7 days before transplant16. In light of our 
Figure 9. Pretransplant MSC infusion modulates graft C4d deposition. (A) Nontreated rats show an extensive C4d deposition both in 
glomeruli and in peritubular capillaries. CsA-treated rats (rats that received a single daily dose of 5 mg/kg cyclosporine by oral gavage 
for 21 days) showed no C4d deposition. The infusion of MSC 7 days before grafting clearly reduced the glomeruli and capillary C4d 
deposition. *p < 0.05 versus nontreated and MSCs-4. (B) Representative microphotographs of C4d from each group.
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results, which in the later phase (4–6 days after infusion) 
saw an anti-inflammatory environment, we may specu-
late that 6–7 days is the time needed for MSCs to induce 
a tolerance status in the immune system. This is therefore 
the most suitable time for receiving a graft.
In conclusion, MSCs by themselves produce changes 
in the immune system; they do not need a pathological 
condition to produce immunomodulatory responses. More 
importantly, the fact that MSCs are not totally ignored 
by the immune system makes them potential candidates 
for alternative immunotherapy in organ transplantation. 
However, the optimal time schedule for MSC infusion 
needs to be considered in future studies.
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